Navigation Links
Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Date:9/14/2007

imed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective for treatment of non-small cell lung cancer, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
6. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
7. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
8. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
9. Analyzers Offer Point-of-Care Lipid Panels
10. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
11. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BARBARA, Calif. , Dec. 23, 2014 In ... Junior Doctors, Association of Sierra Leone , ... Sierra Leone for the treatment of local health ... While a new dedicated Ebola care center was constructed ... virus, the facility is not available for local Sierra Leonean ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... -- Global Information, Inc. (GII) is pleased to announce ... Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" by ... The Insulin Delivery Devices Market is Set to Grow ... 2017 GlobalData estimated the global insulin ...
... N.C., Jan. 13, 2012  Facing patent cliffs and shrinking ... either through in-licensing deals or M&A activities - as ... sound strategy, but a difficult one to effectively put ... a business is fraught with potential pitfalls. With 2012 ...
Cached Medicine Technology:Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
(Date:12/24/2014)... December 24, 2014 Dr. Vu Ho, ... expansion of his practice and med-spa with the addition ... growing list of cosmetic treatments and services. , “Silk ... the skin,” says Dr. Ho. “As a result it ... as wrinkles, sun spots, discolorations or blemishes.” , Similar ...
(Date:12/24/2014)... 24, 2014 Mike Billings , ... with Derek Fenwick, PT, MBA, GCS, Director of ... stem from the passing of the Improving Medicare ... In this taping of the Infinicast, the two leaders ... the Social Security Act to standardize post-acute assessment data ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
(Date:12/24/2014)... 2014 The 2014 Market Research ... and in-depth research report on COC industry. For ... information, including its definition, classification, application, industry chain ... This report also presents product specification, manufacturing process, ... by regions, technology and applications. Analysis also covers ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... study supports raising age for screening, which U.S. is pondering, ... adds evidence to support a growing movement to raise the ... detect cervical cancer. , In England, the recommended age at ... recently raised to 25. In the United States, however, ...
... Researchers have identified MEK4 as a pro-invasion protein and the ... according to a new study published online July 28 in ... Li Xu, M.D., Ph.D., and Raymond C. Bergan, M.D., of ... colleagues investigated the target for genistein in prostate cancer cells ...
... , , , , ... APFC ) today announced that it will release its ... Gibson, Chairman and Chief Executive Officer, invites you to participate in ... , The teleconference will be held Tuesday, August 4, 2009 ...
... , NEW YORK, July 28 Finding time to treat ... during stressful times. Here,s more on a how you can do ... Listen to this report from Kellogg,s at: , ... access video, audio, text, graphics and photos for free and unrestricted use ...
... , , , ... Eleven innovative veterinary students from around the world were ... animals and wildlife. The students, whose projects were funded through ... posters of their results at MAF,s annual meeting in June. ...
... , , BETHESDA, Md., July 28 Hanger ... of $193.5 million for the quarter ended June 30, 2009, an ... prior year. Net income increased $2.0 million, or 25.4%, to ... last year. Earnings per share for the second quarter of 2009 ...
Cached Medicine News:Health News:Teens May Not Benefit from Pap Tests 2Health News:Teens May Not Benefit from Pap Tests 3Health News:American Pacific to Release Financial Results and Hold Fiscal 2009 Third Quarter Investor Teleconference 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 2Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 3Health News:Eleven Veterinary Students Win Top Awards at Morris Animal Foundation's Annual Research Competition 4Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 2Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 3Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 4Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 5Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 6Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 7Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 8Health News:Hanger Orthopedic Group, Inc. Reports $0.31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 9
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: